Comparative Accuracy Analysis of a Real-time and an Intermittent-Scanning Continuous Glucose Monitoring System

Link, Manuela; Kamecke, Ulrike; Waldenmaier, Delia; Pleus, Stefan; García, Arturo Muñiz; Haug, Cornelia; Freckmann, Guido

doi:10.1177/1932296819895022

Cited by 14 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study of 72 diabetic patients evaluated a Dexcom G4 Platinum CGMS with a MARD value of 13% ( 10 ). The study on Dexcom G5 Platinum CGMS indicated a MARD value of 9.5% ( 11 ). In addition, a separate study of Dexcom G6 Platinum CGMS showed a MARD value of 9.0% ( 12 ).…”

Section: Discussionmentioning

confidence: 99%

Accuracy of a novel real-time continuous glucose monitoring system: a prospective self-controlled study in thirty hospitalized patients with type 2 diabetes

Ge,

Zhang,

Wang

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

AimsThe present study aimed to investigate the accuracy of the Glunovo® real-time continuous glucose monitoring system (rtCGMS).MethodsWe conducted a 14-day interstitial glucose level monitoring using Glunovo® rtCGMS on thirty hospitalized patients with type 2 diabetes. The flash glucose monitoring (FGM) was used as a self-control. Consistency tests, error grid analysis, and calculation of the mean absolute relative difference (MARD) were performed using R software to assess the accuracy of Glunovo® rtCGMS.ResultsGlunovo® exhibited an overall MARD value of 8.89% during hospitalization, compared to 10.42% for FGM. The overall percentages of glucose values within ±10%/10, ± 15%/15, ± 20%/20, ± 30%/30, and ±40%/40 of the venous blood glucose reference value were 63.34%, 81.31%, 90.50%, 97.29%, and 99.36% for Glunovo®, respectively, compared with 61.58%, 79.63%, 88.31%, 96.22% and 99.23% for FGM. The Clarke Error Grid Analysis showed that 99.61% of Glunovo® glucose pairs and 100.00% of FGM glucose pairs within zones A and B.ConclusionOur study confirms the superior accuracy of Glunovo® in monitoring blood glucose levels among hospitalized patients with type 2 diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Accuracy of a novel real-time continuous glucose monitoring system: a prospective self-controlled study in thirty hospitalized patients with type 2 diabetes

Ge,

Zhang,

Wang

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…It was previously shown that the FreeStyle Libre deviates systematically by -0.5 mmol/L in people with type 1 diabetes using HemoCue capillary measurements as a reference[ 15 ]. The Dexcom G5 was found to have a MARD of 7.1%-15.7% when tested in people with type 1 diabetes and using a Yellow Spring Instrument as a reference[ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease

Ólafsdóttir¹,

Andelin²,

Saeed³

et al. 2022

WJCC

View full text Add to dashboard Cite

BACKGROUND Advanced chronic kidney disease (CKD) is a common complication for people with type 1 and 2 diabetes and can often lead to glucose instability. Continuous glucose monitoring (CGM) helps users monitor and stabilize their glucose levels. To date, CGM and intermittent scanning CGM are only approved for people with diabetes but not for those with advanced CKD. AIM To compare the performance of Dexcom G5 and FreeStyle Libre sensors in adults with type 1 or 2 diabetes and advanced CKD. METHODS This was a non-randomized clinical trial that took place in two outpatient clinics in western Sweden. All patients with type 1 or 2 diabetes and an estimated glomerular filtration rate (eGFR) of < 30 mL/min per 1.73 m 2 were invited to participate. Forty patients (full analysis set = 33) carried the Dexcom G5 sensor for 7 d and FreeStyle Libre sensor for 14 d simultaneously. For referencing capillary blood glucose (SMBG) was measured with a high accuracy glucose meter (HemoCue ® ) during the study period. At the end of the study, all patients were asked to answer a questionnaire on their experience using the sensors. RESULTS The mean age was 64.1 (range 41-77) years, hemoglobin A1c was 7.0% [standard deviation (SD) 3.2], and diabetes duration was 28.5 (SD 14.7) years. A total of 27.5% of the study population was on hemodialysis and 22.5% on peritoneal dialysis. The mean absolute relative difference for Dexcom G5 vs SMBG was significantly lower than that for FreeStyle Libre vs SMBG [15.2% (SD 12.2) vs 20.9% (SD 8.6)], with a mean difference of 5.72 [95% confidence interval (CI): 2.11-9.32; P = 0.0036]. The mean absolute difference was also significantly lower for Dexcom G5 than for FreeStyle Libre, 1.21 mmol/L (SD 0.78) and 1.76 mmol/L (SD 0.78), with a mean diffrenec of 0.55 (95%CI: 0.27-0.83; P = 0.0004).The mean difference (MD) was -0.107 mmol/L and -1.10 mmol/L ( P = 0.0002), respectively. In all, 66% of FreeStyle Libre values were in the no risk zone on the surveillance error grid compared to 82% of Dexcom G5 values. CONCLUSION Dexcom G5 produces more accurate sensor values than FreeStyle Libre in people with diabetes and advanced CKD and is likely safe to be used by those with advanced CKD.

show abstract

“…This feature allowed caretakers to remotely monitor glucose levels and offer treatment support. The same year, the G5 sensor was released, which incorporated wireless rapid data downloads on a smart phone and/or receiver 61 . The G6 was approved in 2018 as the first iCGM that allowed integration with different insulin pumps, such as Tandem and Omnipod 5 62 , 63 .…”

Section: Glucose Monitoringmentioning

confidence: 99%

Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases

2023

View full text Add to dashboard Cite

Over the past decade there have been many advances in diabetes technologies, such as continuous glucose monitors (CGM CGM : A device that measures glucose values in the subcutaneous space via a sensor and is transmitted to a receiver/smartphone. s), insulin-delivery devices, and hybrid closed loop systems Hybrid Closed Loop (HCL) Systems: An insulin pump able to deliver variable insulin dosages based on CGM values using an algorithm. . Now most CGMs (Medtronic-Guardian, Dexcom-G6, and Abbott-Libre-2) have MARD values of < 10%, in contrast to two decades ago when the MARD used to be > 20%. In addition, the majority of the new CGMs do not require calibrations, and the latest CGMs last for 10–14 days. An implantable 6-months CGM by Eversense-3 is now approved in the USA and Europe. Recently, the FDA approved Libre 3 which provides real-time glucose values every minute. Even though it is approved as an iCGM it is not interoperable with automatic-insulin-delivery (AID) systems. The newer CGMs that are likely to be launched in the next few months in the USA include the 10–11 days Dexcom G7 (60% smaller than the existing G6), and the 7-days Medtronic Guardian 4. Most of the newer CGM have several features like automatic initialization, easy insertion, predictive alarms, and alerts. It has also been noticed that an arm insertion site might have better accuracy than abdomen or other sites, like the buttock for kids. Lag time between YSI and different sensors have been reported differently, sometimes it is down to 2–3 min; however, in many instances, it is still 15–20 min, especially when the rate of change of glucose is > 2 mg/min. We believe that in the next decade there will be a significant increase in the number of people who use CGM for their day-to-day diabetes care.

show abstract

Comparative Accuracy Analysis of a Real-time and an Intermittent-Scanning Continuous Glucose Monitoring System

Cited by 14 publications

References 14 publications

Accuracy of a novel real-time continuous glucose monitoring system: a prospective self-controlled study in thirty hospitalized patients with type 2 diabetes

Accuracy of a novel real-time continuous glucose monitoring system: a prospective self-controlled study in thirty hospitalized patients with type 2 diabetes

Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease

Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases

Contact Info

Product

Resources

About